Skip to content

Personalis, Inc. PSNL Stock-Based Comp

Stock-Based Comp at other companies

Quest Diagnostics logo
Quest DiagnosticsDGX
$20M-9.1%
NeoGenomics logo
NeoGenomicsNEO
$9.64M-10.4%
Illumina logo
IlluminaILMN
$60M-17.8%
Veracyte logo
VeracyteVCYT
$12.76M+16.5%
Guardant Health logo
Guardant HealthGH
$47.61M+26.1%
Natera, Inc. logo
Natera, Inc.NTRA
$95.11M+22.2%

Other financials

Income statement

See full
Revenue$15.5M-24.9%
Gross profit$281.0K-96.1%
Operating income-$32.2M-81.7%
Net income-$30.0M-90.7%
EPS (diluted)-$0.29-61.1%

Balance sheet

See full
Cash & equivalents$73.6M+3.7%
Total debt$39.0M-6.2%
Total equity$254.8M+22.9%
Total assets$325.4M+19.1%

Cash flow

See full
Operating cash flow-$22.5M-25.1%
CapEx$3.2M+27.1%
Free cash flow-$25.7M-25.4%

Valuation

See full
Market cap$1.19B+110%
Enterprise value$1.16B+115%
P/S18.4×+11.8×

Profitability

See full
Gross margin13.7%-19.6pp
Operating margin-158.9%-5,457pp
Net margin-148.1%+154pp
FCF margin-131.2%-453pp

Returns & leverage

See full
Return on equity-41.4%-6.7pp
Debt / equity0.2×0.0×
Current ratio6.6×-0.3×

Where this comes from

Reported directly by Personalis, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Personalis, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Personalis, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Personalis, Inc.'s stock-based comp?
Personalis, Inc. (PSNL) reported stock-based comp of $2.55M in Q1 2026.
How has Personalis, Inc.'s stock-based comp changed year-over-year?
Personalis, Inc.'s stock-based comp increased by 15.1% year-over-year, from $2.22M to $2.55M.
What is the long-term trend for Personalis, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), Personalis, Inc.'s stock-based comp has grown at a -10.0% compound annual growth rate (CAGR), from $14.38M to $9.43M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.